Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer

NCT02012634 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT02012634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02012634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2013
Completion date
December 31, 2018
Enrollment
340 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, capecitabine, triple negative breast cancer